Telix Pharmaceuticals to present theranostic programs and symposia on commercial products at SNMMI.

From GlobeNewswire: 2025-06-19 20:18:00

Telix Pharmaceuticals will present at the SNMMI Annual Meeting with abstracts and symposia on theranostic programs and commercial products. Highlights include a global phase 3 study on TLX591 for advanced prostate cancer and data on Illuccix® impact on decision-making. Two symposia will focus on CAIX-PET imaging in renal cancer and PSMA-PET imaging in prostate cancer. Dr. David N. Cade, Chief Medical Officer at Telix, underscores the company’s commitment to expanding clinical utility. Telix’s diverse portfolio in oncology and collaboration opportunities will be showcased at booth #408. Presentation details and satellite symposia schedules are available for interested attendees.



Read more at GlobeNewswire: Telix Theranostic Programs and Satellite Symposia on